Optic ischaemic neuropathy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:23 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Optic ischaemic neuropathy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Bosentan for Patients with Early Stage Non-Arteritic Anterior Ischemic Optic Neuropathy https://clinicaltrials.eu/trial/study-on-the-effects-of-bosentan-for-patients-with-early-stage-non-arteritic-anterior-ischemic-optic-neuropathy/ Wed, 29 Apr 2026 14:58:28 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-bosentan-for-patients-with-early-stage-non-arteritic-anterior-ischemic-optic-neuropathy/ This clinical trial is focused on studying the effects of a medication called bosentan in patients experiencing an eye condition known as acute non-arteritic anterior ischemic optic neuropathy (NAION). This condition affects the optic nerve, which is crucial for vision, and can lead to sudden vision loss. The trial aims to evaluate how bosentan, taken as a tablet, might help manage this condition during its early stages.

The study involves taking bosentan at a daily dose of 250 mg for two months. Participants will be randomly assigned to receive either the medication or a placebo. The main goal is to assess the impact of bosentan on the visual field, which is the area a person can see without moving their eyes, over a period of three months. The study will also look at other factors such as the thickness of the optic nerve fibers, visual clarity, and certain markers of inflammation in the body.

Throughout the study, participants will undergo various assessments to monitor changes in their vision and overall eye health. These assessments will include tests to measure visual acuity, which is the sharpness of vision, and the visual field. The study will also track blood pressure and other health indicators to ensure the safety and effectiveness of the treatment. The trial is expected to continue until December 2027, providing valuable insights into the potential benefits of bosentan for individuals with NAION.

]]>